Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cenicriviroc (CVC) Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885
View directory record Official record
Conditions
HIV-1-infection, Elevated Cardiovascular Risk
Interventions
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

NCT02120547
View directory record Official record
Conditions
Liver Insufficiency
Interventions
Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

NCT01338883
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

NCT02653625
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cenicriviroc 150 mg
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 19, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

NCT03376841
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Cenicriviroc
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

NCT01827540
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Cenicriviroc, Dolutegravir, Midazolam
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549
View directory record Official record
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 19, 2026, 2:53 PM EDT
Terminated Phase 2 Interventional Results available

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Interventions
Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cenicriviroc, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
View directory record Official record
Conditions
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
Interventions
cenicriviroc
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 19, 2026, 2:53 PM EDT
Terminated No phase listed Observational

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 19, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 19, 2026, 2:53 PM EDT